Chris Bunge
Hedge fund analyst, long/short equity

ANI Pharmaceuticals: Nothin' Generic About It

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals.

ANIP created a very attractive business model, in which it enters markets with few competitors allowing them to increase pricing and improve margins. Their current business model has proven to be highly successful as competition has left the market and they have improved pricing on their two biggest revenue driving products: EEMT & Opium Tincture.

In addition, ANIP has recently acquired 31 products from Teva, which I believe provide material upside from current levels. The acquisition has the added benefit of diversifying the company away from unapproved drugs. After talking to the CEO of ANIP, he stated that they...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details